(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
China’s new condom tax will prove no effective barrier to country’s declining fertility rate - 2Make your choice for a definitive Christmas getaway destination!
- 3Exploring the Market: Unsold Rams May Be Less expensive Than You Naturally suspect
- 4The race is on to turn your body into a GLP-1 factory
- 5Ukraine confirms defence and energy ministers at second attempt
- 6 Vehicle Rental Administrations: Pick Your Ideal Ride
- Instructions to Pick the Right Senior Protection Plan.
- Why Cannes Is the Ultimate New Year’s Eve Destination in the South of France’s Off-Season
- Beneficial Growing Conditions in West Africa Weigh on Cocoa Prices
- Medtronic has 'significant firepower' for multiple acquisitions, executives say
- Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
- 5 Great Youngster Care Administrations To Watch in 2024
- 21 Incredibly Interesting Contemplations To Observe Consistently
- A red meat allergy from tick bites is spreading – and the lone star tick isn’t the only alpha-gal carrier to worry about
